反应详情

Prepared analogously to Compound 1B replacing Compound 1C with 7-amino-4-[1-(4-hydroxybutyl)-1H-pyrazol-4-yl]-2-methyl-2,3-dihydro-1H-isoindol-1-one (Compound 17C, 80 mg, 265 μmol) and to afford 73 mg of the title compound (38%). 1H NMR (400 MHz, CD3OD) δ 8.51 (d, J=8.3 Hz, 1H), 8.30 (s, 1H), 8.06 (s, 1H), 7.89 (s, 1H), 7.83 (d, J=4.8 Hz, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.06 (s, 1H), 6.97 (d, J=8.1 Hz, 1H), 4.54 (s, 2H), 4.24 (t, J=7.1 Hz, 2H), 4.02-4.12 (m, 4H), 3.90 (s, 3H), 3.59 (t, J=6.4 Hz, 2H), 3.34 (d, J=3.5 Hz, 1H), 3.28 (s, 1H), 3.16 (s, 3H), 1.93-2.03 (m, 2H), 1.49-1.60 (m, 2H), 1.26 (t, J=7.1 Hz, 6H). MS (ESI): m/z 718.78 [M+H]+. UPLC: tR=1.20 min (UPLC-SQD: analytical—2 min).